Skip to main content

Table 4 Comparison of patient clinical data with TMTV and TLG

From: Baseline total metabolic tumor volume combined with international peripheral T-cell lymphoma project may improve prognostic stratification for patients with peripheral T-cell lymphoma (PTCL)

Variable No. of patients (n = 84) TMTV TLG
Low (n = 43) High (n = 41) P value* Low (n = 35) High (n = 49) P value*
Sex, F/M 30/54 15/28 15/26 1.000 14/21 16/33 0.499
Age, ≤ 60/> 60 43/41 25/18 18/23 0.275 21/14 22/27 0.191
LDH level, normal/elevated 38/46 24/19 14/27 0.052 21/14 17/32 0.027
B symptoms, no/yes 33/51 23/20 10/31 0.008 18/17 15/34 0.071
ECOG PS, 0–1/ ≥ 2 57/27 35/8 22/19 0.010 28/7 29/20 0.059
Ann Arbor stage, I–II/III–IV 15/69 11/32 4/37 0.087 10/25 5/44 0.043
Extranodal sites ≥ 2, no/yes 65/19 36/7 29/12 0.196 29/6 36/13 0.429
BMB, negative/positive 63/21 36/7 27/14 0.079 28/7 35/14 0.449
Ki-67 ≥ 80%, no/yes 60/24 33/10 27/14 0.336 26/9 34/15 0.807
Platelet cell count, ≥ 150 × 109/L 48/36 24/19 24/17 0.829 22/13 26/23 0.503
IPI, 0–2/3–5 47/37 34/9 13/28 < 0.001 27/8 20/29 0.002
PIT, 0–1/2–4 41/43 29/14 12/29 0.001 24/11 17/32 0.004
IPTCLP, 0–1/2, 3 54/30 31/12 23/18 0.172 26/9 28/21 0.165
  1. A chi-square test was used to test the significance of the association between clinical data and the baseline TMTV and TLG
  2. LDH lactate dehydrogenase, ECOG PS Eastern Cooperative Oncology Group performance status, BMB bone marrow biopsy, IPI International Prognostic Index, PIT prognostic index for T-cell lymphoma, IPTCLP International peripheral T cell lymphoma Project, MTV metabolic tumor volume, TLG total lesion glycolysis
  3. *P < 0.05